Aardvark Therapeutics (NASDAQ:AARD) CEO Buys $96,600.00 in Stock

Key Points

• Aardvark Therapeutics CEO Tien-Li Lee purchased 10,000 shares of the company's stock for a total of $96,600, increasing his ownership to 1,543,384 shares.
• The company's stock recently opened at $9.95 and has seen a 52-week low of $4.88 and a high of $19.58.
• Aardvark Therapeutics reported a quarterly earnings loss of ($0.66) EPS, missing the consensus estimate of ($0.52).

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CEO Tien-Li Lee purchased 10,000 shares of the business's stock in a transaction on Monday, September 15th. The shares were bought at an average cost of $9.66 per share, for a total transaction of $96,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,543,384 shares in the company, valued at $14,909,089.44. This trade represents a 0.65% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Tien-Li Lee also recently made the following trade(s):

• On Friday, September 12th, Tien-Li Lee purchased 5,000 shares of Aardvark Therapeutics stock. The shares were bought at an average cost of $8.50 per share, for a total transaction of $42,500.00.
• On Thursday, September 11th, Tien-Li Lee purchased 6,000 shares of Aardvark Therapeutics stock. The shares were bought at an average cost of $7.82 per share, for a total transaction of $46,920.00.
• On Wednesday, September 10th, Tien-Li Lee bought 9,000 shares of Aardvark Therapeutics stock. The shares were purchased at an average cost of $7.91 per share, for a total transaction of $71,190.00.

Aardvark Therapeutics Price Performance

AARD stock opened at $9.95 on Tuesday. The company's 50-day simple moving average is $10.88 and its 200-day simple moving average is $10.51. Aardvark Therapeutics, Inc. has a 52-week low of $4.88 and a 52-week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Institutional Investors Weigh In On Aardvark Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Aardvark Therapeutics in the second quarter valued at $42,000. Bank of America Corp DE lifted its position in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after acquiring an additional 3,369 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Aardvark Therapeutics in the second quarter valued at $99,000. Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the first quarter valued at $88,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Aardvark Therapeutics in the first quarter valued at $153,000.

Analyst Upgrades and Downgrades

AARD has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Aardvark Therapeutics in a report on Monday, June 30th. They issued a "buy" rating and a $40.00 price objective for the company. Wall Street Zen downgraded shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Royal Bank Of Canada cut their price objective on shares of Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Thursday, August 14th. Finally, Bank of America cut their price target on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, August 28th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $32.60.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.